The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | The TOTAL trial: brentuximab vedotin + gemcitabine in R/R peripheral T-cell lymphoma
Olivier Tournilhac, MD, PhD, Clermont-Ferrand University Hospital, Clermont-Ferrand, France, presents the results of the Phase II study (NCT03496779) investigating the safety and efficacy of the addition of brentuximab vedotin to gemcitabine in patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) expressing ≥5% CD30. Following 4 cycles, 47.9% of patients achieved complete response or partial response. The combination exhibited a good safety profile, with grade ≥3 neutropenia the most common adverse event (AE) exhibited. Longer follow-up studies are mandatory to further explore the benefit of this combination. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
